Cargando…
T-Cell Responses Induced by an Intradermal BNT162b2 mRNA Vaccine Booster Following Primary Vaccination with Inactivated SARS-CoV-2 Vaccine
A practical booster vaccine is urgently needed to control the coronavirus disease (COVID-19) pandemic. We have previously reported the safety and immunogenicity of a fractional intradermal booster, using the BNT162b2 mRNA vaccine in healthy volunteers who had completed two doses of inactivated SARS-...
Autores principales: | Sophonmanee, Ratchanon, Ongarj, Jomkwan, Seeyankem, Bunya, Seepathomnarong, Purilap, Intapiboon, Porntip, Surasombatpattana, Smonrapat, Uppanisakorn, Supattra, Sangsupawanich, Pasuree, Chusri, Sarunyou, Pinpathomrat, Nawamin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9501140/ https://www.ncbi.nlm.nih.gov/pubmed/36146571 http://dx.doi.org/10.3390/vaccines10091494 |
Ejemplares similares
-
Immunogenicity and Safety of an Intradermal BNT162b2 mRNA Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population
por: Intapiboon, Porntip, et al.
Publicado: (2021) -
Regulatory T Cells Decreased during Recovery from Mild COVID-19
por: Seepathomnarong, Purilap, et al.
Publicado: (2022) -
Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population
por: Pinpathomrat, Nawamin, et al.
Publicado: (2022) -
Author Correction: Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population
por: Pinpathomrat, Nawamin, et al.
Publicado: (2022) -
Impaired neutralizing antibodies and preserved cellular immunogenicity against SARS-CoV-2 in systemic autoimmune rheumatic diseases
por: Intapiboon, Porntip, et al.
Publicado: (2022)